Science and Nature

Alzheimer’s drug licensed despite sad outcomes

Abstract

The antibody aducanumab this week grew to alter into the principle contemporary Alzheimer’s disease drug licensed within the US since 2003, and the principle ever that targets to intervene with the underlying disease process. In a controversial decision, the U.S. Food and Drug Administration overruled its advisers to approve aducanumab, an intravenously delivered antibody developed by Biogen and marketed as Aduhelm, based completely on proof that it clears a toxic invent of the protein beta amyloid, which accumulates within the brains of folks with Alzheimer’s and is broadly belief to pressure neuronal wound. The decision came despite skinny and conflicting proof from two extensive scientific trials about the drug’s capacity to gradual patients’ cognitive decline.

Related Articles

Back to top button
%d bloggers like this: